Boston, April 10, 2025 (GLOBE NEWSWIRE) — According to the latest study from BCC Research, “Global DNA Sequencing: Research, Applied and Clinical Markets” is expected to grow from $14.8 billion in 2024 to $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.
This report explores DNA sequencing’s current and future market potential, analyzing drivers, challenges, and opportunities. It covers technologies like next-generation sequencing (NGS), third-generation sequencing (TGS), pyrosequencing, and Sanger sequencing. The market is segmented by product and service, end user, application, and disease category. It also includes profiles of the major companies, analyzing their business segments, financials, and recent market developments. Geographically, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World, with specific countries in each region spotlighted.
The demand for personalized medicine, targeted therapies, and molecular diagnostics is rising. DNA sequencing is increasingly used in oncology, rare disease diagnosis, and prenatal testing, revolutionizing clinical practice and research. The report also focuses on emerging technologies and competitor activity, including product portfolios and patents.
The factors driving the market include:
Technological advances: New sequencing technologies such as next-generation sequencing (NGS) have made DNA sequencing faster, less expensive, and more accurate.
Clinical diagnostics: DNA sequencing helps identify genetic disorders and guide treatments, improving patient care.
Precision medicine: Sequencing provides genetic information for personalized treatments, enhancing the effectiveness of medical care.
Noninvasive prenatal testing: NIPT uses a simple blood test to detect fetal genetic abnormalities, making prenatal care safer and more accurate.
Request a sample copy of the global market for DNA sequencing report.
Report Synopsis
| Report Metric | Details |
| Base year considered | 2023 |
| Forecast period considered |